Browse by CSHL Author

Group by: Item Type | No Grouping
Jump to: Paper
Number of items at this level: 5.

Paper

Zhao, M., Janas, J. A. , Niki, M., Pandolfi, P. P., Van Aelst, L. (April 2006) Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol, 26 (7). pp. 2479-89. ISSN 0270-7306 (Print)

Niki, M., Di Cristofano, A., Zhao, M. M., Honda, H., Hirai, H., Van Aelst, L., Cordon-Cardo, C., Pandolfi, P. P. (December 2004) Role of Dok-1 and Dok-2 in leukemia suppression. Journal of Experimental Medicine, 200 (12). pp. 1689-1695. ISSN 0022-1007

Zhu, J. J., Qin, Y., Zhao, M. M., Van Aelst, L., Malinow, R. (August 2002) Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell, 110 (4). pp. 443-455. ISSN 0092-8674

Zhao, M. M., Schmitz, A. A. P., Qin, Y., Di Cristofano, A., Pandolfi, P. P., Van Aelst, L. (August 2001) Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. Journal of Experimental Medicine, 194 (3). pp. 265-274. ISSN 0022-1007

Di Cristofano, A., Niki, M., Zhao, M. M., Karnell, F. G., Clarkson, B., Pear, W. S., Van Aelst, L., Pandolfi, P. P. (August 2001) p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). Journal of Experimental Medicine, 194 (3). pp. 275-284. ISSN 0022-1007

This list was generated on Thu Oct 10 03:42:22 2024 EDT.